125 related articles for article (PubMed ID: 34877907)
1. Determining similarities of COVID-19 - lung cancer drugs and affinity binding mode analysis by graph neural network-based GEFA method.
Budak C; Mençik V; Gider V
J Biomol Struct Dyn; 2023 Feb; 41(2):659-671. PubMed ID: 34877907
[TBL] [Abstract][Full Text] [Related]
2. Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
Bess A; Berglind F; Mukhopadhyay S; Brylinski M; Alvin C; Fattah F; Wasan KM
Front Pharmacol; 2023; 14():1297924. PubMed ID: 38186640
[No Abstract] [Full Text] [Related]
3. Drug repositioning against COVID-19: a first line treatment.
Bibi N; Farid A; Gul S; Ali J; Amin F; Kalathiya U; Hupp T
J Biomol Struct Dyn; 2022; 40(23):12812-12826. PubMed ID: 34519259
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
Apaydın ÇB; Çınar G; Cihan-Üstündağ G
Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
9. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
Elmaaty AA; Darwish KM; Khattab M; Elhady SS; Salah M; Hamed MIA; Al-Karmalawy AA; Saleh MM
J Biomol Struct Dyn; 2022; 40(19):8866-8893. PubMed ID: 33928870
[TBL] [Abstract][Full Text] [Related]
10. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
11. Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors.
Kumawat A; Namsani S; Pramanik D; Roy S; Singh JK
J Biomol Struct Dyn; 2022; 40(20):9897-9908. PubMed ID: 34155961
[TBL] [Abstract][Full Text] [Related]
12. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
14. Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.
Pauly I; Kumar Singh A; Kumar A; Singh Y; Thareja S; Kamal MA; Verma A; Kumar P
Curr Pharm Des; 2022; 28(46):3677-3705. PubMed ID: 36345244
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
[TBL] [Abstract][Full Text] [Related]
16. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
[TBL] [Abstract][Full Text] [Related]
17. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment.
Taibe NS; Kord MA; Badawy MA; Shytaj IL; Elhefnawi MM
Ther Adv Respir Dis; 2022; 16():17534666221132736. PubMed ID: 36282077
[TBL] [Abstract][Full Text] [Related]
18. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
19. Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
Ishola AA; Adewole KE; Tijjani H; Abdulai SI; Asogwa NT
J Biomol Struct Dyn; 2022 Oct; 40(17):7726-7743. PubMed ID: 33749538
[TBL] [Abstract][Full Text] [Related]
20. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
Paul SS; Biswas G
Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
